key: cord-1025576-k89md1xg
authors: Long, Brit; Chavez, Summer; Carius, Brandon M.; Liang, Stephen Y.; Brady, William J.; Koyfman, Alex; Gottlieb, Michael
title: Clinical update on COVID-19 for the emergency and critical care clinician: Medical management
date: 2022-03-26
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2022.03.036
sha: 9cebcac617282dfc96c0623cf5a2de13c3a90e74
doc_id: 1025576
cord_uid: k89md1xg

INTRODUCTION: Coronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved. OBJECTIVE: This is the second part in a series on COVID-19 updates providing a focused overview of the medical management of COVID-19 for emergency and critical care clinicians. DISCUSSION: COVID-19, caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. A variety of medical therapies have been introduced for use, including steroids, antivirals, interleukin-6 antagonists, monoclonal antibodies, and kinase inhibitors. These agents have each demonstrated utility in certain patient subsets. Prophylactic anticoagulation in admitted patients demonstrates improved outcomes. Further randomized data concerning aspirin in outpatients with COVID-19 are needed. Any beneficial impact of other therapies, such as colchicine, convalescent plasma, famotidine, fluvoxamine, ivermectin, and vitamins and minerals is not present in reliable medical literature. In addition, chloroquine and hydroxychloroquine are not recommended. CONCLUSION: This review provides a focused update of the medical management of COVID-19 for emergency and critical care clinicians to help improve care for these patients.

supplemental oxygen, with no association between steroids and serious adverse events (9) (10) (11) (12) . A meta-analysis of 7 randomized controlled trials (RCTs) found an odds ratio (OR) of 0.66 (95% confidence interval (CI) 0.53 to 0.82) and a reduction in mortality by 8% (32% from 40%) with use of steroids in critically patients with COVID-19 (11) . This meta-analysis found dexamethasone in particular was associated with reduced mortality (odds ratio [OR] 0.64, 95% confidence interval [CI] 0.50 to 0.82), but methylprednisolone was evaluated in one included RCT with 47 patients and was not associated with reduced mortality (OR 0.91, 95% CI 0.29 to 2.87) (11) . Current guidelines recommend dexamethasone be used in hospitalized patients with either severe or critical disease (defined as oxygen saturation ≤ 94% on room air or on supplemental oxygen, admitted to the intensive care unit [ICU] , septic shock, mechanically ventilated, extracorporeal membrane oxygenation [ECMO] , end organ dysfunction, or acute respiratory distress syndrome [ARDS]) (9, 10) . Steroids should not be used in patients with COVID-19 who do not require oxygen supplementation.

Most recommendations for steroid administration include dexamethasone, which lacks mineralocorticoid activity and likely has minimal effect on sodium and fluid balance (18) .

Dexamethasone may be given 6 mg IV or PO for either 10 days or until discharged in those requiring supplemental oxygen (10, 18) . The COVID STEROID 2 trial included 982 patients and compared dexamethasone 12 mg versus 6 mg in patients with COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. Authors found no difference in median number of days alive without life support (adjusted mean difference 1.3 days, 95% CI 0 to 2.6 days) or mortality at 28 days (27.1% vs. 32.3%, adjusted J o u r n a l P r e -p r o o f relative risk 0.86, 95% CI 0.68 to 1.08) (14) . However, this study may have been underpowered to detect a difference in delays alive without life support or mortality (14) .

A preplanned secondary analysis of the COVID STEROID 2 trial including patients with severe hypoxia (those requiring > 10 L of oxygen or on noninvasive ventilation) found that when compared with 6 mg daily, 12 mg daily for up to 10 days increased days alive without life support by 1.3 days, with no difference in adverse events (14) . The CoDEX study found that patients with COVID-19 and moderate to severe ARDS treated with higher dose IV dexamethasone (20 mg once daily for 5 days followed by 10 mg daily for 5 days or until ICU discharge in combination with standard care) had greater ventilatorfree days compared to standard care alone (6.6 days vs. 4.0 days; difference 2.26 days, 95% CI 0.2 to 4.38) (15) . One single center retrospective study found methylprednisolone 1 mg/kg/day for ≥3 days was associated with reduced risk of 50-day mortality versus dexamethasone 6 mg/day for ≥7 days in mechanically-ventilated patients only (RR 0.480, 95% CI 0.235 to 0.956) (16) . In patients not requiring mechanical ventilation, both steroids reduced mortality, with no difference in overall mortality between methylprednisolone and dexamethasone (RR 0.635, 95% CI 0.326 to 1.218) (16) .

However, a retrospective study including 1379 patients of receiving steroids suggests higher doses (≥ 40 mg daily methylprednisolone equivalent dosing) are associated with a greater odds of in-hospital mortality (OR 2.14, 95% CI 1.45 to 3.14) and decreased odds of requiring dialysis (OR 0.33, 95% CI 0.18 to 0.63), with no difference in hospitalassociated infections (OR 1.00, 95% CI 0.59 to 1.68), need for invasive mechanical ventilation (OR 0.77, 95% CI 0.40 to 1.46), or hospital readmissions (OR 1.14, 95% CI J o u r n a l P r e -p r o o f Journal Pre-proof 0.74 to 1.76) (17) . However, this study was retrospective and included admitted patients with varying degrees of illness severity.

Based on the available data, patients with critical illness such as ARDS or those requiring mechanical ventilation may benefit from higher doses of steroids (dexamethasone 20 mg IV) although this is controversial (15) . If dexamethasone is unavailable, an equivalent alternative steroid may be used such as methylprednisolone 32 mg, prednisone 40 mg, or hydrocortisone 160 mg (10, (18) (19) (20) (21) . Patients who are hospitalized with COVID-19 classified as non-severe and thus not requiring supplemental oxygen should not receive steroids; similar recommendations exist for non-hospitalized patients (10, 18) .

Inhaled steroids have been evaluated, specifically inhaled budesonide and inhaled and intranasal ciclesonide. The non-placebo-controlled steroids in COVID-19 (STOIC) trial included 139 patients within 7 days of onset of mild COVID-19 symptoms randomized to budesonide (two inhalations, twice daily, 400 mcg per actuation) versus usual care until symptom resolution (22) . Fewer patients required medical evaluation or admission compared with those assigned to usual care (intention to treat analysis 3% vs. 15%, difference in proportions 0.123, 95% CI 0.033 to 0.213), with a number needed to treat with "other therapies" (azithromycin, colchicine, doxycycline, and hydroxychloroquine) in patients > 65 years or those > 55 years with comorbidities who were symptomatic for up to 14 days with suspected COVID-19 but not admitted (23 A multicenter double blind RCT evaluated ciclesonide 320 micrograms twice per day versus placebo in 400 outpatients 12 years and older with symptomatic confirmed COVID-19 (24) . Time to symptom alleviation was similar (19 days in both groups), and there was no difference in hospital admissions. Authors state there was a difference in the combined secondary outcome of ED visits or hospitalization (1.0% vs. 5.4%, p = 0.03), but there was no difference in hospitalizations alone (24) . Another RCT evaluated inhaled ciclesonide 600 micrograms twice per day and intranasal ciclesonide 200 micrograms daily versus placebo (25) . Authors included 203 symptomatic patients 18 years and older with COVID-19 within 6 days of symptom onset. There was no difference in self-reported resolution of symptoms by day 7 (adjusted risk difference 5.5%, 95% CI -7.8% to 18.8%) or day 14. The RCT was also stopped early with no prespecified endpoint (25) . Currently, there is not clear evidence that inhaled or intranasal steroids significantly improve patient outcomes, and further RCTs are needed. Remdesivir is the only currently recommended antiviral for hospitalized patients, and it may also be used in the outpatient setting as a 3-day regimen (9, 10, (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . It inhibits viral RNA polymerase and may speed recovery (9,10). ACTT-1 was a double-blind RCT including 1059 hospitalized patients with COVID-19 and found patients receiving remdesivir had a median recovery of 10 days, compared to 15 days in those not receiving the medication (rate ratio for recovery 1.29, 95% CI 1.12 to 1.49) (28) . This benefit was predominantly observed in those requiring low flow supplemental oxygen but not other airway treatments (e.g., NIPPV, HFNC, mechanical ventilation) (28 IDSA guidelines conditionally recommend the use of remdesivir in patients (outpatient or hospitalized) with mild-to-moderate COVID-19 who are at risk for progression to severe disease, regardless of the need for supplemental oxygen (10) . The NIH recommends remdesivir in admitted patients requiring supplemental oxygen. The NIH also recommends it as the third line therapy in the outpatient setting ( (36, 37) . Of note, remdesivir may be active against the Omicron variant, but in vitro and in vivo evidence is limited (33) (34) (35) 38) .

Novel oral antivirals include nirmatrelvir/ritonavir and molnupiravir (33, 34, (37) (38) (39) (40) (41) (42) (43) (44) . As of approval (33, 34, (37) (38) (39) (40) (41) (42) (43) (44) . Paxlovid is a combination of two protease inhibitors: J o u r n a l P r e -p r o o f nirmatrelvir, a protease inhibitor, and ritonavir, a pharmacokinetic booster (33, 34, (37) (38) (39) (40) (41) .

It is approved for use in those over 12 years and at least 40 kilograms, and based on NIH guidelines as of February 15, 2022, is the current first line recommended therapy for outpatients who meet criteria for treatment (33, 34) . An interim analysis of phase 2/3 of the randomized Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) trial included 2246 unvaccinated adult outpatients with COVID-19 with symptom onset no more than 5 days before randomization and at least one risk factor for severe disease (39, 40) . Patients were randomized to receive 300 mg of nirmatrelvir and 100 mg of ritonavir versus placebo twice daily for 5 days. Patients were excluded if there was an anticipated need for hospitalization within 48 hours after randomization and prior receipt of convalescent plasma or SARS-CoV-2 vaccine. Patients receiving nirmatrelvir/ritonavir within 3 days of symptom onset were found to have a reduced risk of hospitalization and death compared to those who received placebo by 6.32 percentage points (95% CI -9.04 to -3.59, relative risk reduction 89.1%), with 0 deaths in the treatment groups compared to 7 deaths in the placebo group. Viral load was lower in the treatment groups when treatment was initiated within 3 days of symptom onset (0.8% versus 7%, p<0.0001) (39, 40) . The incidence of adverse events was similar between the groups. Patients with no high risk features also demonstrated reduced rates of hospitalization and decreased viral loads with Paxlovid (39, 40) . Paxlovid interacts with over 28 other medications, with several contraindications including renal impairment, liver impairment, and hypersensitivity to nirmatrelivr or ritonavir ( Table 2 ). Based on limited in vitro evidence and structural properties, Paxlovid is expected to be effective against Omicron (33, 34, 38, 39) .

Molnupiravir is a nucleoside analogue which inhibits SARS-CoV-2 replication, approved for use in those over age 18 years. Indications include positive test for SARS-CoV-2, symptomatic for 5 days or fewer, high risk for progression to severe disease, and the patient does not require hospitalization (Table 2) (33, 34, (42) (43) (44) . An international phase 3 randomized control trial reported interim results with 775 patients demonstrating a reduced risk of hospital admission or death with molnupiravir (7.3% versus 14.1%, p=0.0012), with no deaths in the group receiving molnupiravir (42) . A phase 3, doubleblind RCT evaluated molnupiravir in 1433 unvaccinated outpatients within 5 days of onset of signs or symptoms of COVID-19 and at least one risk factor for severe illness (43) . Patients were randomized to molnupiravir 800 mg or identical placebo twice daily for 5 days. Patients were excluded if there was an anticipated need for hospitalization within the next 48 hours, dialysis or glomerular filtration rate < 30 ml/min/1.73m2, pregnancy, severe neutropenia, platelets < 100,000/mL, SARS-CoV-2 vaccination, and unwilling to use contraceptives during the intervention period and for at least 4 days after regimen completion. Authors found reduced hospitalization and death through 29 days in the molnupiravir group compared to placebo (6.8% versus 9.7%; difference −3.0 percentage points; 95% CI −5.9 to −0.1) (43) . Molnupiravir should be avoided in pregnancy, breastfeeding is not recommended until 4 days after course conclusion, and men should use contraception for 3 months after use (33, 34, 44) . Limited in vitro data suggest molnupiravir is effective against Omicron (33, 34, 38, 44) . antagonists had more organ support-free days (median 10 days for tocilizumab, 11 days for sarilumab, and 0 days in the control group) and lower hospital mortality (tocilizumab OR (52) . The authors found that tocilizumab was associated with reduced mechanical ventilation or death (HR 0.56, 95% CI 0.33 to 0.97) but not the secondary outcome of mortality alone (HR 1.14, 95% CI 0.92 to 1.42) compared to the placebo group (52). CRP elevation was not an inclusion criterion in the EMPACTA trial (Tocilizumab 124.50 mg/L, placebo 143.40 mg/L, overall 136.10 mg/L) (52) . In the RECOVERY trial, hospitalized patients with hypoxia or on supplemental oxygen with CRP ≥ 75 mg/L were randomized to either standard care or standard care with an initial weight-based dose of tocilizumab (49) . A second dose was given 12-24 hours if the patient had not improved clinically. Although most patients were given systemic steroids (3,385/4,116; 82%), patients given tocilizumab were more likely to be discharged from the hospital by 28 days (57% versus 50%, rate ratio 1.22, 95% CI 1.22 to 1.33). For patients not requiring mechanical ventilation at baseline, those in the tocilizumab group were less likely to progress to death or invasive mechanical ventilation (35% compared to 42%, risk ratio 0.84, 95% CI 0.77 to-0.92) (49).

There are concerns of superinfection, hepatotoxicity, thrombocytopenia, and leukopenia with IL-6 antagonists, but current data suggest no significant difference in adverse events when compared with placebo or standard care (9, 10, (45) (46) (47) (48) (49) (50) (51) (52) . The WHO recommends patients with severe or critical COVID-19 infections should be given both steroids and IL-6 antagonists simultaneously (9) . NIH guidelines recommend tocilizumab or sarilumab only in combination with dexamethasone (or other steroid equivalent) for select admitted patients with COVID-19 and respiratory decompensation (defined as patients admitted to the ICU in the previous 24 hours requiring HFNC > 40% FiO2, noninvasive ventilation [NIV], or mechanical ventilation), as well as recently admitted patients requiring HFNC or NIV with significantly elevated inflammatory markers (45) .

Monoclonal antibodies are manufactured antibodies that can provide a transient but immediate effect against SARS-CoV-2 (9,10,33,34,39,40,53-67). These antibodies include bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, tixagevimab, and cilgavimab (9, 10, 33, 34, 39, 40, (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) . Although in vitro data suggest this class of drugs continues to be effective against the Delta variant, emerging evidence suggests limited efficacy against newer variants, such as Omicron (33, 34, 54) . Furthermore, if monoclonal antibody treatment is given before vaccination for either prophylaxis or treatment, vaccination should be delayed 30 or 90 days, respectively, as it may adversely impact the developing immune response (54, 68) . In patients who are vaccinated, this does not apply and should not affect timing of or decision to use monoclonal antibody J o u r n a l P r e -p r o o f treatment (54) (55) (56) . Bamlanivimab is an antibody treatment used in combination with etesevimab, but due to reduced efficacy against variants, is no longer recommended by the NIH (54) . The combination of casirivimab and imdevimab (also known as REGN-COV2 or REGEN-COV TM ) has demonstrated activity against the SARS-CoV-2 spike protein prior to the Omicron variant and may be used in non-hospitalized adults with mild to moderate COVID-19 at risk of decompensation (9, 54, (57) (58) (59) . In a systematic review and network meta-analysis, casirivimab-imdevimab was the only monoclonal antibody that lowered the risk of hospitalization in patients with non-severe disease with moderate certainty data (57) .

Monoclonal antibodies may be more effective in patients with non-severe rather than severe disease and may also be used to prevent infection in high-risk patients, with a meta-analysis of 47 trials which evaluated several COVID therapies finding lower risk of Sotrovimab was studied in the COMET-ICE trial, which included 583 high-risk outpatients with COVID-19 within 5 days of symptom onset (61) . High risk was defined as age > 55 years, diabetes, body mass index > 30, chronic kidney disease, heart failure, chronic obstructive pulmonary disease, and moderate-to-severe asthma. There was a lower rate of disease progression leading to death or hospitalization at 29 days in the sotrovimab group compared to the placebo group (1% vs 7%, RR reduction 85%, p=0.002) (61) . Sotrovimab retains activity against the Omicron variant spike protein based on a single pre-print in vitro study, but further data are needed (33, 34, 62) . The NIH recommends sotrovimab as the second line treatment for patients in the outpatient setting who meet treatment criteria (Table 2) (33, 34, 54) .

Evusheld is a long-acting antibody combination by AstraZeneca consisting of tixagevimab and cilgavimab ( 

Kinase inhibitors include baricitinib, imatinib, ruxolitinib, and tofacitinib (9, 33, 34) .

These medications inhibit JAK 1, JAK 2, and intracellular kinase, reducing inflammation.

The ACTT-2 trial compared baricitinib and remdesivir versus remdesivir alone in 1033 hospitalized patients across 8 countries, finding more rapid recovery in the baricitinib and remdesivir group (7 days vs. 8 days, rate ratio for recovery 1.16, 95% CI 1.01 to 1.32) and higher likelihood or clinical improvement at 15 days (OR 1.3, 95% CI 1.0 to 1.6), which was predominantly seen in patients receiving high flow oxygen or noninvasive ventilation (rate ratio for recovery 1.51, 95% CI 1.10 to 2.08) (69) . This trial, however, (10) . Antibiotics in these patients should be considered. The Dutch Working Party on Antibiotic Policy recommends utilizing sputum cultures, blood cultures, and pneumococcal urinary antigen testing to identify those who may benefit from antibiotics (77) . If these tests are negative after 48 hours, discontinuation of empiric antibiotics initiated on admission can be considered (77) . 

Non-hospitalized patients with COVID-19 should not receive prophylactic anticoagulants or antiplatelet therapy without a specific indication or participation in a clinical trial (78) (79) (80) . While the NIH recommends anticoagulation in all hospitalized nonpregnant adults with COVID-19, the American Society of Hematology recommends consideration of prophylactic-dose anticoagulation on admission for critically-ill patients, and there is variation between several society recommendations based on illness severity of COVID-19 disease and presence of VTE risk factors (Table 3 , 4) (78-85). Table 3 . COVID-19 anticoagulation regimens (78) (79) (80) (81) (82) (83) (84) (85) . (96) . Patients receiving aspirin had a shorter duration of hospital stay (median 8 days versus 9 days) and greater likelihood of discharge from the hospital alive within 28 days (RR 1.06, 95% CI 1.02 to 1.10). Aspirin was associated with reduced thrombotic events (absolute reduction 0.6%, standard error 0.4%) but also increase in major bleeding events (1.6% versus 1.0%, absolute increase 0.6%, standard error 0.2%). There was no reduction in progression to invasive mechanical ventilation or death (RR 0.96, 95% CI 0.90 to 1.03) (96) .

Investigations of antiplatelet therapies outside of aspirin alone do not consistently demonstrate improved patient outcomes and were nevertheless largely dominated by aspirin therapy. A large study of nearly 35,000 patients > 50 years old demonstrated improved benefits for those taking antiplatelet therapy prehospital to those who did not for in-hospital mortality (18.9% vs. 21.5%, p < 0.001) and a 2.6% absolute reduction in mortality (HR 0.81, 95% CI 0.76-0.87, p < 0.005) (97) . However, most patients were J o u r n a l P r e -p r o o f taking aspirin (83.9%), with less on clopidogrel (8.2%), dual antiplatelet therapy (7.4%), or ticagrelor or prasugrel, and the authors did not break down differences between therapies. The ACTIV-4a multicenter RCT compared heparin anticoagulation alone to added P2Y12 inhibitor administration (ticagrelor or clopidogrel) and found no significant benefit amongst 2,219 non-critically ill patients, including no difference in days free of respiratory or cardiovascular support and major thrombotic events (98) . Similar trials with much smaller populations of less than 100 patients on antiplatelet therapy, most on aspirin, found no significant mortality benefit compared to controls (99, 100) .

In the initial period of the pandemic, several medications were theorized to be effective against COVID-19. These include chloroquine (CLQ) and hydroxychloroquine (HCQ), colchicine, convalescent plasma, famotidine, fluvoxamine, ivermectin, and vitamin and mineral supplements. Most of these were based largely on perceived successes in initial case reports and case series, but subsequent trials found inconsistent efficacy and concerns for increased risk of adverse events.

CLQ and HCQ were initially theorized to improve patient outcomes in COVID-19 through an antiviral effect, but multiple studies found no benefit and even increased risk of mortality with their use (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) . These medications have significant risk of toxicity, most notably electrolyte derangements and cardiovascular complications, including J o u r n a l P r e -p r o o f Journal Pre-proof potentially fatal QTc prolongation (103) (104) (105) 112) . Lack of efficacy and increased mortality led to the revocation of the FDA EUA in June 2020 (113) and the discontinuation of the HCQ arm in the WHO SOLIDARITY trial the following month (104, 114) . Currently, IDSA and NIH strongly recommend against the use of CLQ and HCQ for treating COVID-19 given the level of risk without significant benefit in COVID-19 (10, 115) . This extends to prophylactic use in healthcare workers, as clinical trials demonstrated no significant benefit in preventing viral illness (10, 116, 117) .

As an anti-inflammatory agent, colchicine is theorized to reduce the diffuse hyperinflammatory state of COVID-19 and improve patient recovery (118) (119) (120) (121) . Several RCTs demonstrated decreased duration of supplemental oxygen and lower rates of pneumonia development with use of colchicine in COVID-19. However, colchicine was associated with increased risk of gastrointestinal side effects and rates of pulmonary embolism and no significant differences in mortality (118, 119, 122) . Despite enthusiasm from a small initial Italian study showing mortality benefit in patients receiving colchicine compared to standard care, the majority of evidence to-date, including several larger trials and meta-analyses, have found no significant mortality benefit for colchicine (118, (120) (121) (122) (123) (124) (125) (126) . At this time, there is insufficient evidence to support the use of colchicine in COVID-19 patients. The NIH specifically recommends against colchicine use in admitted patients and states that there is insufficient evidence for outpatient use (126) .

Convalescent plasma has been utilized in prior viral pandemics including SARS, H 1 N 1 influenza, and Ebola Virus Disease (57, 101, 127, 128) . Convalescent plasma has a theoretical benefit in COVID-19, as this is plasma obtained from donors who have recovered from COVID-19 and may contain antibodies that can suppress viral replication (101, (127) (128) (129) (130) (131) (132) ). An initial report described 5 critically-ill patients in China with improvement in ARDS following initiation of convalescent plasma, and other similarly small case series demonstrated patient improvement (101, 130, 131) . Larger trials showed significant improvement in those treated with high-titer plasma compared to low-titer groups, driving enthusiasm further and prompting an initial FDA EUA (10, 57, 128, 129, 132, 133) . However, these early studies demonstrate significant issues with confounders, and more recent high-quality trials and meta-analyses have found no significant benefit for the use of convalescent plasma in the treatment of COVID-19 (10, 57, (127) (128) (129) 134, 135) . Much of this lack of benefit may come from the period of infection the patient is admitted to the hospital and treated. The majority of patients will be admitted later in the disease course after they have started creating antibodies and are clearing the virus, and thus convalescent plasma will not benefit. At this time, both the IDSA and NIH recommend against convalescent plasma use in general patient populations (10, 129) .

The proposed mechanism of action for famotidine centers on competitive inhibition of two essential SARS-CoV-2 protease enzymes that allow for viral docking (136, 137) .

Journal Pre-proof However, in-vitro studies are inconsistent, and this theory has been disputed (136, 137) .

Retrospective analyses early in the COVID-19 pandemic found that small populations given famotidine had a reduced risk of intubation and death (136) (137) (138) (139) (140) . Several of these analyses were limited by significant heterogeneity in formulations and dosing of famotidine, including some patients already taking the medication prior to hospitalization (136, 138) . Additionally, several studies employed famotidine at more than double the standard dose or simultaneously used intravenous and oral formulations, prompting concerns for increased side effect risks (137, 139) . Subsequent larger trials and metaanalyses demonstrated no reduction in mortality (141) (142) (143) . Current IDSA guidelines state that famotidine should not be used solely to treat COVID-19 disease (10).

Fluvoxamine is an antidepressant that may reduce inflammation and progression to severe disease in those with mild COVID-19 through activity at the sigma-1 receptor. An RCT conducted in Brazil including 1497 unvaccinated outpatients with COVID-19 diagnosed within 7 days and at least 1 risk factor for severe disease found fluvoxamine 100 mg twice per day for 10 days reduced rates of hospitalization at 28 days (11% versus 16%, RR 0.68, 95% CI 0.52-0.88) (144) . However, the definition of hospitalization included an ED length of stay for at least 6 hours, and most of the reductions in hospitalization were due to decrease in ED visits (144) . There was no change in mortality, viral clearance at day 7, need for mechanical ventilation, length of mechanical ventilation, or days hospitalized (144) . A double-blind RCT evaluated 15 days of fluvoxamine compared to placebo in patients with confirmed COVID-19 within 7 days of symptoms J o u r n a l P r e -p r o o f Journal Pre-proof (145) . Of the 152 enrolled patients, 115 completed the trial. Authors found fluvoxamine reduced clinical deterioration compared with placebo (0% versus 8.3%, 95% CI 1.8%-16.4%), but the study was stopped early (145) . Current trials suffer from significant methodological issues, and thus clear recommendations for fluvoxamine cannot be made at this time.

Ivermectin is an effective antiparasitic with multiple proposed mechanisms of action against SARS-CoV-2, including inhibition of viral transfer and replication in vitro and anti-inflammatory effects based on prior studies of other viruses (e.g., Zika, Dengue) (146) (147) (148) (149) (150) . Current evidence based on higher quality data suggests no benefit (151) (152) (153) .

While several early studies suggested reduced mortality, shortened recovery time, and decreased transmissibility benefits with ivermectin in the treatment of COVID-19 patients, these studies suffered from major limitations, including wide heterogeneity, poor subject allocation, limited or no blinding, and inadequate controls with risk of confounding (10, (146) (147) (148) (149) (150) (151) (152) (153) . Additionally, many studies employed dosing regimens larger than those previously approved for parasitic infections, increasing the risks of side effects (10, 148, 152) . A meta-analysis released in 2021 including 10 RCTs found no improvement in all-cause mortality, length of stay, or viral clearance in patients with mild COVID-19 (151) . An RCT including 409 patients 50 years and older with mild-tomoderate COVID-19 within 7 days of symptom onset found no change in progression to severe disease (RR 1.25, 95% CI 0.87 to 1.80), as well as no difference in ICU admission, mechanical ventilation, and 28-day in-hospital death with ivermectin (153) . Furthermore, J o u r n a l P r e -p r o o f the IDSA and NIH recommend against its use in both inpatient and outpatient settings for COVID-19 (10, 154) .

Vitamin C has been evaluated for its theorized immunomodulation and free radical scavenging benefits in systemic illness. However, a limited number of recent small trials and meta-analyses provide low-quality data suggesting no benefits in mortality, mechanical ventilation metrics, or hospital stay in COVID-19 patients (155) (156) (157) (158) . Earlier studies demonstrated concerns of worse patient outcomes in COVID-19 patients with zinc deficiency, prompting examination of zinc supplementation in COVID-19 treatment regimens (163, 164) . However, recent trials find no significant benefits in symptom duration, recovery time, hospitalization, or mortality (157) . Currently the NIH recommends against zinc supplementation above the recommended dietary allowance in COVID-19 patients outside of clinical trials, and the NIH states there is insufficient evidence for or against the use of vitamin C or D (147, 161, 152, 165) .

The COVID-19 pandemic has led to over 5. 

COVID-19) pandemic

COVID-19

Coronavirus Disease (COVID-19): A primer for emergency physicians

Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS

COVID-19 respiratory support in the emergency department setting

Point-of-Care Ultrasound for Intubation Confirmation of COVID-19 Patients

COVID-19 cardiac arrest management: A review for emergency clinicians

A living WHO guideline on drugs for covid-19

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America 2022

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Dexamethasone in Hospitalized Patients with Covid-19

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19

Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients

National Institute of Health

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe

Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With

Symptomatic COVID-19: A Randomized Clinical Trial

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

FDA approves first treatment for COVID-19. News release. U.S. Food and Drug Administration

ASHP COVID-19 resource center

Remdesivir for the Treatment of Covid-19 -Final Report

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

What's New in the Guidelines

Nonhospitalized Patients With Mild to Moderate COVID-19. National Institutes of Health

National Institutes of Health

WHO recommends against the use of remdesivir in COVID-19 patients. WHO

Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. Pfizer

EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel. European Medicines Agency

Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck

MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Emergency Use Authorization 108. U.S. Food and Drug Administration

Interleukin-6 in Covid-19: A systematic review and meta-analysis

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. Ann Intensive Care

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality

Among Patients Hospitalized for COVID-19: A Metaanalysis

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

National Institutes of Health

SARS-CoV-2 variant classifications and definitions

Neutralizing monoclonal antibodies for treatment of COVID-19

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

PHASE 3 TRIAL SHOWS REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) ANTIBODY COCKTAIL REDUCED HOSPITALIZATION OR DEATH BY 70% IN NON-HOSPITALIZED COVID-19 PATIENTS. REGENERON. MARCH 23

Regeneron Reports Positive Interim Data With Regen-Cov™ Antibody Cocktail Used as Passive Vaccine to Prevent Covid-19. REGENERON

COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. biorxiv

Evusheld long-acting antibody combination authorized for emergency use in the US

Fact sheet for healthcare providers: Emergency use authorization for Evusheld. Food and Drug Administration

Phase III double-blind, placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult. (PROVENT). ClinicalTrials.gov

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

Phase III double-blind, placebo-controlled study of AZD7442 for post-exposure prophylaxis of COVID-19 in adults (STORM CHASER)

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

STOP-COVID Trial Investigators. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Janus Kinase Inhibitors and Bruton's Tyrosine Kinase Inhibitors. National Institutes of Health

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy

Co-infections in people with COVID-19: a systematic review and meta-analysis

Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline

Antithrombotic Therapy in Patients With COVID-19. National Institutes of Health

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

COVID-19 and VTE-Anticoagulation

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Physician experiences in management of COVID-19-associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

ACTIV-4a Investigators

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial

Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease

Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study

Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis

Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates

The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Treatment options for COVID-19: The reality and challenges

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal

Primum non nocere -Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Biosci Trends

Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians

Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. U.S. Food and Drug Administration

WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. World Health Organization

National Institutes of Health

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial

Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)

Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials

Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev

Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

National Institutes of Health

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

National Institutes of Health

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

COVID-19 convalescent plasma EUA decision memo. U.S. Food and Drug Administration. www.fda.gov/media/141480

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

What Underlies the Benefit of Famotidine Formulations Used During COVID-19?

Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients

Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System

TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Ivermectin for preventing and treating COVID-19

Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Misleading clinical evidence and systematic reviews on ivermectin for COVID-19

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial

National Institutes of Health

Vitamin C and COVID-19 treatment: A systematic review and meta-analysis of randomized controlled trials

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19: A protocol for systematic review and metaanalysis

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial

National Institutes of Health

Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev

Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?

National Institutes of Health

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

COVID-19: Poor outcomes in patients with zinc deficiency

The Potential Impact of Zinc Supplementation on COVID-19

National Institutes of Health

 Table 4 . Society recommendations on VTE prophylaxis in COVID-19 patients (78) (79) (80) (81) (82) (83) (84) (85)